← All trials
NCT06066580
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 2, 2023
- Primary completion
- Mar 31, 2028
- Completion date
- Mar 31, 2028
- First posted
- Oct 4, 2023
- Last posted
- Nov 7, 2023
- Enrollment
- 200
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Edgewise Therapeutics, Inc.Lead sponsor
- Medpace, Inc.Collaborator
- Edgewise Therapeutics, Inc.Study chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.